Circassia, a specialty biopharmaceutical company, has announced positive results from a Phase II clinical study of its anti-allergy technology, ToleroMune, in the field of cat allergy.
The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients.
Circassia conducted the double-blind study in Germany, where patients with a confirmed history of cat allergies received a single dose of ToleroMune therapy or placebo. The 88 study participants were divided into groups, with each receiving a different dose, either via subcutaneous or intradermal injection to compare the two routes of administration.
To test the effect of the treatment, patients received a microscopic dose of cat dander (the main allergen responsible for cat allergies) into their skin several weeks later.
Patients who received ToleroMune therapy via the most effective administration route had markedly reduced skin reactions to the cat allergen at all of the five dose levels tested compared with placebo. The most effective dose reduced reactions by over 40%, compared with 10% for placebo.
Throughout the study the ToleroMune treatment proved well tolerated, with no serious or severe adverse events experienced in any of the groups, despite the steadily increasing doses.
Steve Harris, Circassia’s CEO, said: “Our goal for ToleroMune is to provide a range of allergy therapies that effectively and quickly treat the underlying disease while also offering excellent safety. Consequently, these positive clinical results will not only contribute to the development of our cat allergy product, but will also provide the foundations for our other allergy programs that utilize our ToleroMune technology.”
Comments